

# ZOGENIX

## Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

August 1, 2014

SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer in order to pursue another opportunity. In the interim, Roger Hawley, the Company's Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer and lead the continued launch and commercial activities.

"Scott has laid a solid foundation for our expanded commercial team and we wish him success in his new endeavor," commented Roger Hawley, Chief Executive Officer. "Our experienced commercial team is already fully engaged in carrying out all planned activities and we expect continued growth without disruption. I look forward to leading the sales, marketing, managed care and trade teams to further direct focus to the commercial success of the Company."

Mr. Hawley, one of the co-founders of Zogenix, has extensive experience in leading commercial organizations with his prior experience at multiple pharmaceutical companies.

### About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

### Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: the continued efforts related to the commercialization of Zogenix products and the ability to carry out planned activities without disruption. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: Zogenix's dependence on its remaining key personnel; Zogenix may be unable to achieve broad market acceptance and generate significant revenues from sales of its products; and other risks detailed in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACT: Investors

Zack Kubow | The Ruth Group  
646.536.7020 | [zkubow@theruthgroup.com](mailto:zkubow@theruthgroup.com)

Zogenix